MedTrace Logo

A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants

NCT05156034 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-03-13

No results posted yet for this study

Summary

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics (PK) of SRK-001 in Healthy Participants.

Conditions

  • Healthy Participants

Interventions

DRUG

SRK-001

Participants will receive IV doses of SRK-001.

DRUG

Placebo

Participants will receive IV doses of placebo.

Sponsors & Collaborators

  • Sarkana Pharma Inc

    lead OTHER

Principal Investigators

  • Study Director · Sarkana Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-21
Primary Completion
2022-09-05
Completion
2022-09-05
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05156034 on ClinicalTrials.gov